Mechanism of Action
GIPR Signaling and Incretin Effect
GIP binds GIPR (Gs-coupled GPCR) on pancreatic beta cells, elevating cAMP and potentiating glucose-stimulated insulin secretion in a glucose-dependent manner. Unlike sulfonylureas, GIP does not cause hypoglycemia at normal glucose levels. GIPR is also expressed in adipose tissue, bone (anabolic effects), and brain (appetite modulation).
Adipose Tissue and Weight Paradox
GIP promotes triglyceride storage in adipocytes via GIPR. However, tirzepatide's superior weight loss vs GLP-1 agonists alone implies GIPR agonism in the context of dual agonism enhances weight loss, possibly through altered adipose partitioning and enhanced CNS satiety signaling.
Research Summary
Tirzepatide (Dual GIP/GLP-1 Agonist)
FDA ApprovedTirzepatide demonstrated 20-22% body weight reduction in SURMOUNT-1 at 15 mg weekly, significantly exceeding semaglutide. HbA1c reductions of 2.0-2.3% in T2DM trials outperform all prior agents. The dual mechanism provides additive/synergistic effects on beta cell function, appetite suppression, and metabolic rate.
Bone Metabolism
Preclinical/ClinicalGIPR on osteoblasts promotes bone formation; GIPR knockout mice show reduced bone mass. GIP levels rise postprandially, linking nutrient intake to bone anabolism. This GIP-bone axis may explain why bariatric surgery can increase fracture risk despite weight loss.
Cardiovascular Effects
PreclinicalGIPR is expressed in heart and vasculature. GIP has direct cardioprotective effects in ischemia-reperfusion models. Tirzepatide cardiovascular outcomes data (SURPASS-CVOT) is being collected.
Calculate your GIP dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| T2DM treatment (tirzepatide) | 5-15 mg SC weekly | Weekly | Subcutaneous |
| Obesity treatment (tirzepatide) | Start 2.5 mg weekly, escalate to 15 mg | Weekly | Subcutaneous |
| GIPR pharmacology (in vitro) | 1-100 nM | Single concentration-response | Cell-based assay |
Native GIP not administered therapeutically due to rapid DPP-4 degradation. Tirzepatide is the approved dual agonist.
Interactions
Safety Profile
Tirzepatide adverse effects: nausea, vomiting, diarrhea (class incretin effects, typically mild-moderate and transient); possible increased pancreatitis risk (class warning); thyroid C-cell tumor signal in rodents (not established in humans). Contraindicated in MEN2 or medullary thyroid carcinoma history. Not WADA listed.
References
- [1]Brown JC, et al. Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res. 1975;31:487-532.
- [2]Jastrzebska M, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
- [3]Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes. Lancet Diabetes Endocrinol. 2016;4(6):525-536.